5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback